JAK2 inhibitor TG101348 overcomes erlotinib-resistance in non-small cell lung carcinoma cells with mutated EGF receptor

Non-small cell lung cancer (NSCLC) patients with epidermal growth factor receptor (EGFR) mutations are responsive to EGFR-tyrosine kinase inhibitor (EGFR-TKI). However, NSCLC patients with secondary somatic EGFR mutations are resistant to EGFR-TKI treatment. In this study, we investigated the effect...

Descripción completa

Detalles Bibliográficos
Autores principales: Zhang, Fu-quan, Yang, Wen-tao, Duan, Shan-zhou, Xia, Ying-chen, Zhu, Rong-ying, Chen, Yong-bing
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Impact Journals LLC 2015
Materias:
Research Paper
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4546470/
https://www.ncbi.nlm.nih.gov/pubmed/25869210

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4546470/
https://www.ncbi.nlm.nih.gov/pubmed/25869210

Ejemplares similares